These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 36504951)

  • 1. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
    Xu R; Wang W; Zhang W
    Front Public Health; 2022; 10():1039123. PubMed ID: 36504951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
    Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
    JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics - a global data-based analysis.
    Meo SA; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9470-9476. PubMed ID: 37843359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
    Sah R; Rais MA; Mohanty A; Chopra H; Chandran D; Bin Emran T; Dhama K
    Int J Surg Open; 2023 Jun; 55():100625. PubMed ID: 37255735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.
    Zhou Y; Zhi H; Teng Y
    J Med Virol; 2023 Jan; 95(1):e28138. PubMed ID: 36097349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
    Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
    Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).
    Chrysostomou AC; Vrancken B; Haralambous C; Alexandrou M; Gregoriou I; Ioannides M; Ioannou C; Kalakouta O; Karagiannis C; Marcou M; Masia C; Mendris M; Papastergiou P; Patsalis PC; Pieridou D; Shammas C; Stylianou DC; Zinieri B; Lemey P; The Comessar Network ; Kostrikis LG
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2022 Jul; 28():e937676. PubMed ID: 35775166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Feikin DR; Higdon MM; Andrews N; Collie S; Deloria Knoll M; Kwong JC; Link-Gelles R; Pilishvili T; Patel MK
    Vaccine; 2023 Mar; 41(14):2329-2338. PubMed ID: 36797097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.
    Sharma D; Notarte KI; Fernandez RA; Lippi G; Gromiha MM; Henry BM
    J Med Virol; 2023 Jan; 95(1):e28241. PubMed ID: 36263448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau.
    Xu C; Wang J; Yu L; Sui X; Wu Q
    Front Public Health; 2022; 10():1029171. PubMed ID: 36703829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
    Nazmunnahar ; Ahmed I; Islam MR
    Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clinical Outcomes and Imaging Features in Hospitalized Patients with SARS-CoV-2 Omicron Subvariants.
    Lee JE; Hwang M; Kim YH; Chung MJ; Jeong WG; Sim BH; Jeong YJ
    Radiology; 2023 Jul; 308(1):e230653. PubMed ID: 37462497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
    Viruses; 2023 May; 15(6):. PubMed ID: 37376600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.
    Lewnard JA; Hong VX; Patel MM; Kahn R; Lipsitch M; Tartof SY
    Nat Med; 2022 Sep; 28(9):1933-1943. PubMed ID: 35675841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.